Overview
On May 21, 2026, Eli Lilly announced positive topline results from TRIUMPH-1, the pivotal Phase 3 clinical trial for retatrutide in adults with obesity or overweight and at least one weight-related comorbidity. The data represent the most compelling weight-loss efficacy results published for any pharmacological agent to date.
Retatrutide (GLP-3) is a first-in-class triple hormone receptor agonist — simultaneously activating GLP-1, GIP, and glucagon receptors — distinguishing it mechanistically from both semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP dual agonist).
Key TRIUMPH-1 Findings
At 80 weeks of weekly subcutaneous dosing:
For context, the highest-dose tirzepatide (15 mg weekly) produced ~22.5% weight loss in the SURMOUNT-1 trial at 72 weeks, and semaglutide 2.4 mg produced ~15% in the STEP-1 trial at 68 weeks. Retatrutide at 12 mg represents a roughly 6 percentage-point improvement over tirzepatide — translating to an additional 15 lbs of weight loss for a 250-pound person.
Lead investigator Dr. Ania Jastreboff of Yale School of Medicine noted that "clear improvements in assessed cardiometabolic health measures" were also recorded throughout the study.
TRIUMPH-4: Osteoarthritis Benefits
In December 2025, Eli Lilly published Phase 3 TRIUMPH-4 data — the first trial specifically evaluating retatrutide in adults with obesity and knee osteoarthritis.
Key findings at 68 weeks:
This dual benefit — substantial weight loss alongside meaningful pain relief — positions retatrutide as a potentially transformative option for the large population of patients with obesity-associated osteoarthritis.
Side Effect Profile
The side effect profile in TRIUMPH-1 was consistent with the GLP-1 drug class:
Discontinuation rates due to adverse events were 12.2% and 18.2% for 9 mg and 12 mg respectively, compared to 4.0% with placebo. These rates were correlated with baseline BMI — patients with higher BMI had lower discontinuation rates, consistent with the drug's primary effect.
A small proportion of participants with lower baseline BMI discontinued due to perceived excessive weight loss.
Head-to-Head: Retatrutide vs Tirzepatide
A separate Phase 3 trial (NCT06662383) directly comparing retatrutide to tirzepatide is currently enrolling 800 participants, with primary completion estimated for late 2026. This head-to-head data will be critical for clinical adoption decisions.
Triple Agonism: Why the Mechanism Matters
Retatrutide's glucagon receptor agonism is the primary mechanistic differentiator:
The glucagon component drives energy expenditure beyond what GLP-1 or dual agonists achieve alone — explaining the additional weight loss magnitude. The key challenge historically with glucagon agonism was hyperglycemia risk; retatrutide's GLP-1 component appears to offset this effectively.
Timeline to Approval
Based on TRIUMPH program progress:
Eli Lilly has seven additional Phase 3 trials in the TRIUMPH program evaluating retatrutide across obesity, type 2 diabetes, and comorbidity indications.
Research Context
The site's retatrutide protocol pages cover the 5 mg, 10 mg, and 15 mg vial formats currently available for research. The Phase 3 trial utilized 9 mg and 12 mg weekly doses — noting that Phase 2 data established 8 mg and 12 mg as the most effective doses, with the 12 mg dose producing approximately 24% weight reduction at 48 weeks in the published NEJM Phase 2 paper.
For researchers studying GLP-3 receptor agonism, TRIUMPH-1 confirms that the triple mechanism produces meaningfully superior efficacy compared to single and dual agonists across a 2-year research horizon.
Important Note
Retatrutide is not FDA-approved and remains investigational. All information presented here is for educational and research reference only.